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Abstract
Familial amyloid polyneuropathy (FAP) is caused by mutations of the transthyretin (TTR)
gene, predominantly expressed in the liver. Two compounds that knockdown TTR, compris-
ing a small interfering RNA (siRNA; ALN-TTR-02) and an antisense oligonucleotide (ASO;
IONIS-TTRRx), are currently being evaluated in clinical trials. Since primary hepatocytes
from FAP patients are rarely available for molecular analysis and commercial tissue culture
cells or animal models lack the patient-specific genetic background, this study uses primary
cells derived from urine of FAP patients. Urine-derived cells were reprogrammed to induced
pluripotent stem cells (iPSCs) with high efficiency. Hepatocyte-like cells (HLCs) showing
typical hepatic marker expression were obtained from iPSCs of the FAP patients. TTR
mRNA expression of FAP HLCs almost reached levels measured in human hepatocytes.
To assess TTR knockdown, siTTR1 and TTR-ASO were introduced to HLCs. A significant
downregulation (>80%) of TTRmRNA was induced in the HLCs by both oligonucleotides.
TTR protein present in the cell culture supernatant of HLCs was similarly downregulated.
Gene expression of other hepatic markers was not affected by the therapeutic oligonucleo-
tides. Our data indicate that urine cells (UCs) after reprogramming and hepatic differentia-
tion represent excellent primary human target cells to assess the efficacy and specificity of
novel compounds.
Introduction
Transthyretin (TTR) related amyloidosis (ATTR) represents a class of life-threatening and
progressing diseases that is associated with the misfolding of TTR, a major blood protein
and a carrier of retinol (vitamin A) and thyroxine (T4) [1]. TTR is primarily (>95%) pro-
duced in the liver as a tetramer. Amyloid aggregation is believed to be a result of decreased
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tetramer stability resulting in dissociation of TTR into monomers [2,3]. In vitro studies
revealed that monomeric TTR is prone to unfolding and ultimately followed by self-assem-
bly into oligomers and amyloid fibrils [4,5]. Amyloid TTR fibrils are frequently found in
peripheral neurons, gastrointestinal tract and heart. In hereditary ATTR with polyneuropa-
thy, also known as familial amyloid polyneuropathy (FAP), the peripheral nerves are primar-
ily affected, while in cardiomyopathy-related TTR amyloidosis, also known as familial
amyloid cardiomyopathy (FAC), neuropathy is usually less prominent or even absent.
Patients mostly develop a severe disease and die within 5 to 15 years after onset. While these
ATTR forms can be ascribed to a dominant expression of the TTR gene variants, only wild
type TTR is expressed in senile systemic amyloidosis (SSA), a type of amyloidosis frequently
found in elderly people [6,7].
Until recently, the only treatment option for patients having FAP was liver transplanta-
tion. Of note, transplantation results in the inhibition of variant TTR synthesis, while the
wild type TTR is produced at a high level [8]. Unfortunately, there is a limited availability of
organs and transplantation is associated with significant morbidity. At an early stage of the
disease, FAP patients carrying the ATTRV30M variant benefit the most from transplanta-
tion. However, worsening of the disease, e.g. neuropathy, is frequently observed in the recipi-
ents over time [9]. Moreover, amyloid deposition continues in the patients indicating that
variant TTR is no longer responsible for progression of the disease. An alternate therapy
includes small molecules, such as Tafamidis. Tafamidis has been approved in Europe for the
therapy of adult FAP patients with stage 1 polyneuropathy, targeting the stabilization of the
TTR tetramer. The progression of the disease was shown to be reduced after administration
of Tafamidis [10–12].
Suppression of the variant TTR synthesis by interference with mRNA has been reported for
ribozymes demonstrating the feasibility of this approach [13,14]. However, biochemical and
clinical evidence suggests that the wild type TTR can also significantly contribute to the disease
[15,16]. It is therefore conceivable that mitigating the overall TTR synthesis can address the
current demand for an efficient therapy of ATTR. Small interfering RNAs (siRNAs) and anti-
sense oligonucleotides (ASOs) are the most commonly used strategies for silencing gene
expression [17,18]. ASOs are short single-stranded stretches of DNA or RNA with comple-
mentary sequence to their target mRNA, while siRNAs are double-stranded and afford activa-
tion by the enzyme complex Dicer. Due to the advances in the modification of the
oligonucleotides, including changes to the nucleotide chemistry that increase the resistance of
the oligonucleotides to degradation, siRNAs and ASOs have recently evaluated in clinical trials
[19–22]. For therapy of FAP, two novel compounds, ALN-TTR02 and IONIS-TTRRx, are cur-
rently under clinical investigation [23–28]. ALN-TTR02 is a lipid nanoparticle-formulated
siRNA [29], whereas IONIS-TTRRx is a second generation antisense gapmer, both targeting
human variant and wildtype TTRmRNA.
Induced pluripotent stem cells (iPSCs), mostly derived from fibroblasts, have been postu-
lated to model disease [30] and were also used to generate hepatocyte-like cells (HLCs) of FAP
patients [31,32]. Recently, urine cells (UCs) were reported as a novel source for reprogramming
[33–36]. Isolation of UCs for generation of iPSCs exhibits several advantages (i) accessibility is
given at any time point as urine is an inexhaustible source, (ii) procedures are independent
from age and gender, (iii) cell isolation techniques are simple and UCs can be easily expanded
using standard cell culture conditions, (iv) procedures are excellently suited to be integrated
into the routine clinical practice. We have therefore utilized UCs as a patient-friendly source
for somatic cell isolation. In this study, we addressed whether FAP patient-derived UCs are
suited to obtain a set of HLCs, representing various geno- and phenotypes of the disease, for
the evaluation of novel TTR-specific siRNA and ASO compounds.
TTR Knockdown in FAP HLCs
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Materials and Methods
Ethics Statement
All experiments were approved by the ethics committee of the University Clinic of Muenster
and written informed consent was obtained from all patients and individuals enclosed in the
study. The characterization of FAP patients is given according to the previously suggested
nomenclature [37].
Isolation and Cultivation of UCs
Spontaneously voided urine was collected and processed as described [38,39]. One well of a
12-well cell culture plate (Greiner Bio-One) was precoated with 0.1% gelatin (Millipore). Urine
samples were centrifuged at 400 x g for 10 minutes. Cell pellets were washed with PBS (Sigma-
Aldrich) / 1% penicilline-streptomycine (PAA) and resuspended in 1 ml of UC medium con-
sisting of DMEM/F-12 (Gibco), 10% FCS (PAA), 1% penicilline-streptomycine (PAA), MEM
non-essential amino acid solution (NEAA, Sigma-Aldrich), 1x GlutaMAX-I (Gibco), 0.1 mM
2-Mercaptoethanol (Gibco) and SingleQuot Kit CC-4127 REGM (Lonza). Cells were incubated
at 37°C, 5% CO2 for 24 hours. 1 ml of fresh UC medium was added for three days. Half of the
media was changed every second day. At a cell confluence of 80–90%, cells were washed and
detached using trypsin/EDTA (Gibco). After addition of trypsin inhibitor (DTI, Gibco), cells
were resuspended in 2 ml of UC medium.
Reprogramming of UCs
At a cell confluence of 80–90%, UCs were harvested by trypsinization. 0.5 x 106 cells were
reprogrammed using the Amaxa Basic Nucleofector Kit for Primary Mammalian Epithelial
Cells (Lonza, VPI-1005) according to the protocol of the manufacturer. 1 μg of each vector
pCXLE-hOCT3/4-shp53-F, pCXLE-SK and pCXLE-hUL (addgene) was used. The cells were
transferred to the Matrigel1matrix (Corning) coated well. After 24 hours, the UC medium
was replaced by mTeSR-1 (Stemcell Technologies), supplemented with 1% penicilline-strepto-
mycine and changed every second day. Cells were subcultured every 5 to 7 days. For further
passaging, iPSCs were dissociated with 1 U/ml Dispase (Stemcell Technologies).
DNA Sequencing
For detection of patient-specific TTR variant, the chromosomal DNA was isolated using
QIAamp DNA mini kit (Qiagen) and the genotype was determined by DNA sequencing using
Big Dye Version 3.1 (Life Technologies).
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA, Electron Microscopy Sciences) for 30 min-
utes, washed with PBS and permeabilized with 0.5% Triton X-100 (Fisher Scientific) in PBS for
15 minutes. Cells were blocked with 3% BSA (Sigma-Aldrich), followed by incubation at 4°C
with primary antibody (S1 Table). After washing, cells were incubated with a secondary anti-
body for 1 hour. Cells were counterstained with DAPI (Sigma-Aldrich) and visualized (Olym-
pus CKX41-X10; cellSens Standard 1.11 imaging software).
Real-Time qRT-PCR
Total RNA was isolated using RNeasy kit (Qiagen). For first-strand cDNA synthesis, 1 μg of
RNA was applied to SuperScript II Reverse Transcriptase (Invitrogen) according to the
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instructions of the manufacturer. 1 μl of the reverse transcriptase product was mixed with
SYBER Green PCR Core Plus (Eurogentec) and 150 nM of primers (S2 Table) were added.
PCR was analyzed on the ABI Prism 7900 HT Sequence Detection System (PE Applied Biosys-
tems) by using a 3-stage program for 2 min at 50°C, 10 min at 95°C, and 40 cycles of 14 sec at
95°C, 1 min at 60°C. Data were analyzed by SDS 2.4 software (PE Applied Biosystems). Ct val-
ues were normalized to GAPDH or UBQLN1 (2-ΔΔCt). As an internal control, RNA was derived
from primary human hepatocytes (PHH) derived from donor organs after whole liver perfu-
sion and cryopreservation.
Embryoid Body Formation
iPSCs were treated with Dispase to generate small iPSC clusters. Cell clusters were centrifuged
at 200 x g for 5 minutes, resuspended in 2 ml embryoid body medium as described in the man-
ual (TaqMan1 hPSC Scorecard™) and transferred to one well of 6-well suspension culture
plate (Greiner Bio-One). The medium was changed daily and after 7 days of cultivation, cell
pellets were collected for RNA isolation. Evaluation of the trilineage differentiation potential of
iPSCs was examined using the 384-well hPSC Scorecard™ Panel (Life Technologies) and evalu-
ated by the Thermo Fisher Cloud hPSC Scorecard Analysis software.
Generation of HLCs
Hepatic induction of iPSCs was accomplished as described previously with minor modifica-
tions [39–41]. In brief, single cells were generated after Accutase incubation (Sigma-Aldrich)
for 6–8 minutes. Cells were resuspended in mTeSR-1 and transferred to Matrigel-precoated
cell culture plates. After 24 hours, culture medium was changed for the next 3 days to DMEM/
F12 supplemented with 100 ng/ml recombinant Activin-A (R&D Systems), 100 ng/ml fibro-
blast growth factor-2 (FGF2, Peprotech), 50 ng/ml recombinant humanWnt3a (R&D Sys-
tems). Concentration of KnockOut SR Xenofree CTS (KSR, Gibco) was 0%, 0.2% and 2.0% for
the first, second and third day, respectively. For the next 8 days, cells were cultivated in
DMEM/F12 supplemented with 10% KSR, 1mMNEAA, 1mM L-Glutamine, 1% dimethyl sulf-
oxide (DMSO, Sigma-Aldrich), and 100 ng/ml hepatocyte growth factor (HGF, Peprotech).
Finally, cells were grown for 3 days in 10% KSR, 1mmol/L NEAA, 1mM L-Glutamine, and
0.1μM dexamethasone (Sigma-Aldrich).
Flow Cytometry
1 x 106 cells were fixed with 4% PFA for 30 minutes, washed with PBS and permeabilized.
After blocking, a 1:100 dilution of antibody was added for 30 minutes. Secondary antibody
staining (1:100) was performed for 30 minutes. Cells were analyzed in a Coulter Epics
XL-MCL (Beckman Coulter).
Periodic Acid-Schiff Staining
At day 14 of hepatic differentiation, cells were analyzed for glycogen synthesis and storage by
Periodic Acid-Schiff (PAS) staining using the system protocol (Sigma-Aldrich, 395B-1KT).
Analysis of Cell Culture Supernatants
Total supernatant was separated on a 12.5% SDS polyacrylamide gel, and blotted onto Amer-
sham Protran Premium 0.45 NC (GE Healthcare Life Sciences). The membrane was blocked
overnight at 4°C in Tris-buffered saline (TBS) containing 0.05% Tween 20 (TBS-T, Sigma-
Aldrich) and 5% non-fat dry milk (AppliChem). After washing with 0.05% TBS-T, the
TTR Knockdown in FAP HLCs
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membrane was incubated with a polyclonal rabbit anti-TTR antibody (S2 Table) diluted 1:500
and incubated for two hours at room temperature. Horseradish peroxidase (HRP)-linked sec-
ondary antibody was used (GE Healthcare Life Sciences). Amersham ECLWestern Blotting
Detection Reagent (GE Healthcare Life Sciences) was added. Blots were quantified using Ima-
geJ 1.48v analysis software. TTR of cell culture supernatants was analyzed using liquid chroma-
tography-high resolution accurate mass MS (LC-HRAMMS) in positive-ion mode.
siRNA and ASO Incubation
siTTR1 and TTR-ASO were generated according to the procedures used for synthesis of
ALN-TTR02 and IONIS-TTRRx, respectively. At day 14 of hepatic differentiation, the medium
of HLCs was changed to Opti-MEM (Gibco). Lipid nanoparticle-formulated siTTR1 was
added at 0.3 μM to the medium. TTR-ASO (1.5 μM) was complexed with 2.5 μl Lipofecta-
mine1 2000 Reagent (Life Technologies) prior to transfer to the culture medium of HLCs. The
culture medium was changed daily.
Statistical Analysis
Statistical analysis was performed by Kruskal-Wallis 1-way ANOVA and Student’s t-test using
SPSS 22.0 software. Data are given as mean ± standard error (SE).
Results
Isolation of Urine Cells from FAP Patients
Urine samples of 21 FAP patients (8 female, 13 male, mean age 52.1 ± 13 years) were processed
for isolation and cultivation of renal tubular cells. In total, outgrowth of UCs was achieved with
12 FAP patients (57.1%). The efficacy of UC cultivation could be increased when a second
donation was available. Urine from healthy donors (n = 10; mean age 43.0 ± 16) showed a
somewhat higher efficacy (70.0%) [38,42,43]. Female and male FAP donors showed almost the
same efficacy of UC isolation (50.0% and 61.5%, respectively). The age of FAP patients, the
TTR variant or the absolute volume of the urine donation did not affect the efficacy of UC gen-
eration (data not shown). Of note, 80 ml of urine was sufficient for generation of UCs in one
FAP patient. Typically, 2 to 6 million UCs were obtained after 2 to 3 weeks at a passage number
of 2 (p2). Contamination of the UC-derived cell cultures were observed in two preparations
(6.9%). The morphology of the UCs presented a typical smooth-edged shape and cobble stone-
like appearance (Fig 1A) and immunocytochemistry stainings indicated the expression of epi-
thelial and renal proximal tubular markers (data not shown) confirming similar observations
in previous reports [33]. UCs were recently reported to express markers of mesenchymal stem
cells [42]. A flow cytometry analysis of the UCs was performed using markers typically present
or absent on mesenchymal stem cells [44], e.g. CD13, CD29, CD71, CD105, CD166 (present)
and CD34 (absent). Epithelial markers CD13 and CD29 were found to be highly expressed in
UCs whereas CD34, CD71, CD105 and CD166 were not detected (Fig 1B). qRT-PCR analysis
confirmed a high expression of epithelial, fibroblast and renal markers in the UCs (Fig 1C).
Reprogramming of UCs from FAP Patients
UCs from five FAP patients at p2 were selected for reprogramming (Table 1). Two of the five
FAP patients express ATTRV30M which represents the most frequent TTR variant worldwide.
The variants ATTRG47A and ATTRR34T are found worldwide and have a high prevalence in
German FAP patients. The selected FAP patients show various clinical manifestations, either
presymptomatic or with early and late onset of disease. The UCs were reprogrammed by
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transient expression of the factors OCT4, SOX2, KLF4, L-MYC, LIN28, and an shRNA against
p53 [39,45]. The resulting cell lines gave rise to typical iPSC-like colonies within 10 to 20 days
after nucleofection as judged by morphology (Fig 2A). After reprogramming, the pluripotent
character of the cells was assessed by immunocytochemistry for the expression of embryonic
Fig 1. Characterization of urine cells. (A) Brightfield image of UCs at p2 after isolation. FAP3 derived cells are shown as
one typical example. Scale bar, 100 μM. (B) Flow cytometry analysis of UCs at p2 (n = 4). Total expression of markers
used for characterization of mesenchymal stem cells is given. (C) Relative mRNA expression of epithelial, fibroblast and
renal marker genes in UCs (n = 6). Data were normalized to housekeeping gene.
doi:10.1371/journal.pone.0161455.g001
Table 1. Characteristics of FAP patients.
Name Gender Age Variant Phenotype
FAP1 F 33 ATTRV30M Neuropathy, early onset
FAP2 F 70 ATTRV30M Neuropathy, late onset
FAP3 F 54 ATTRG47A Presymptomatic
FAP4 M 51 ATTRG47A Cardiac, neuropathy
FAP5 M 59 ATTRR34T Neuropathy, cardiac
doi:10.1371/journal.pone.0161455.t001
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stem (ESC) cell-specific markers OCT3/4, SSEA-4, TRA-1-60 and NANOG (Fig 2B). Real-
time qRT-PCR analysis revealed that OCT3/4, NANOG and SOX2 were highly expressed in
the cells (Fig 2C). To further assess the pluripotency of the reprogrammed cells, formation of
embryoid bodies (EB) was employed. Trilineage differentiation potential of the urine-derived
FAP cells was close to a set of 13 functionally characterized hES and iPS reference cell lines
[46] with a modest bias to the mesodermal lineage (Fig 2D; S1 Fig). To confirm that the TTR
Fig 2. Reprogramming of urine cells obtained from FAP patients. (A) Typical brightfield images of UCs from a FAP
patient at different times after reprogramming. FAP2 derived cells are shown. Scale bars, 100 μM. (B)
Immunofluorescence stainings of cells after reprogramming. DAPI was used for nuclear counterstaining. FAP5 derived
cells are shown as one typical example. Scale bars, 50 μM. (C) Gene expression analysis of reprogrammed cells. Relative
expression to housekeeping gene is shown. Mean±SE of FAP1 to FAP5 are shown. (D) EB expression profile of
pluripotency- and lineage-specific markers derived from FAP iPSCs. Dots indicate sample scores of cells derived from
patients FAP1 (black), FAP2 (red) and FAP4 (green). Human embryonic stem (hES) and iPS cell lines served as control
(box plot). (E) DNA sequencing chromatograms of the TTR gene derived from FAP iPSCs. Heterozygotic variant
nucleotides are shown by arrow.
doi:10.1371/journal.pone.0161455.g002
TTR Knockdown in FAP HLCs
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variant was not altered in the reprogrammed cells, the chromosomal DNA was isolated and
subjected to sequence analysis (Fig 2E). The 3’ end of the TTR gene which is indispensable as a
target for knockdown was also analyzed by DNA sequencing (data not shown). In summary,
the data reveal that reprogramming of the UCs obtained from FAP patients result in high
expression of pluripotency markers, typical of iPSCs, and retention of TTR variant gene
sequences. Two clones of iPSCs were examined throughout the study.
Differentiation of FAP iPS Cells toward Hepatocyte-Like Cells
The five generated FAP iPS cell lines were subjected to a hepatic differentiation protocol as
described previously [39,40]. The cell morphology changed significantly within the first two
days of treatment (Fig 3A). Gene expression analysis indicated a major change of the expres-
sion levels for pluripotency and hepatic markers (S2 Fig). At day 14 of hepatic differentiation,
cells displayed a polygonal shape, binucleation, and an increased nuclear-cytoplasmic ratio
typical for human hepatocytes (magnification given in Fig 3A). Immunocytochemistry stain-
ings for human albumin, TTR, HNF4a and AFP indicate that the expression of major hepato-
cyte-specific markers was upregulated in the cells (Fig 3B). Flow cytometry analysis (Fig 3C)
confirmed human albumin expression in up to 90.1% of the cells (mean 70.7 ± 18). The gly-
cogen synthesis of the differentiated cells was assessed by PAS staining, indicating the pres-
ence of a major function of human hepatocytes (Fig 3D). Notably, TTRmRNA expression
was highly expressed in differentiated cells at day 14 (Fig 3E). TTR upregulation was several
orders of magnitude higher as compared to iPSCs and almost reached the expression level of
human hepatocytes. qRT-PCR analysis revealed the upregulation of definitive endodermal
and various hepatocyte marker genes as compared to iPSCs (Fig 3F). Mass spectral analyses
of cell culture supernatants derived from the differentiated cells identified both, the secreted
wild-type TTR and the mutant TTR form at almost equal ratios (Fig 3G). The data indicate
that differentiation of iPSCs derived from UCs of FAP patients result in hepatocyte-like cells
(HLCs) that are excellently suited to study the effect of therapeutic oligonucleotides directed
against TTR.
TTR Knockdown in FAP HLCs by siRNA and Antisense Clinical Study
Compounds
The siRNA and antisense compounds ALN-TTR02 and IONIS-TTRRx that are directed against
human TTR are currently being evaluated in clinical studies for therapy of FAP patients
[23,26]. The efficacy of these compounds was assessed in the established five HLCs. An almost
complete silencing of TTRmRNA was observed in all five HLCs after 24 hours. Knockdown of
TTRmRNA by siTTR1 and TTR-ASO was about 80 to 90% (Fig 4A) whereas scrambled con-
trol oligonucleotides did not show any significant downregulation (data not shown). Compari-
son of TTR knockdown between individual FAP cell lines revealed minor variability (S3 Fig).
Both compounds were equally effective in HLCs derived from healthy individuals suggesting
that wildtype TTRmRNA is targeted with the same efficacy (S4 Fig). Assessment of cell-associ-
ated TTR expression by immunocytochemistry suggested that both compounds almost
completely blocked TTR protein synthesis, while at the same time albumin and alpha-fetopro-
tein expression remained unchanged(Fig 4B; S5 Fig). To validate the impact of the compounds
on secreted TTR, a Western blot analysis was performed using the cell culture supernatants
derived from the HLCs. Both the monomeric and the dimeric form of TTR were significantly
downregulated after addition of the two compounds (Fig 4C). Densitometric quantification of
TTR-specific bands revealed a downregulation between 80% to 90% (Fig 4D). The non-specific
off-target effects of siTTR1 and TTR-ASO were determined in FAP HLCs by qRT-PCR
TTR Knockdown in FAP HLCs
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Fig 3. Generation of FAP iPS cell-derived hepatocyte-like cells. (A) Brightfield images of iPSCs at different
days after in vitro differentiation. FAP5 derived cells are shown as one typical example. Scale bars, 100 μM. Arrows
in the zoomed area point to binucleated cells. (B) Immunofluorescence stainings of cells at day 14 of differentiation.
FAP4 derived cells are shown as one typical example. Scale bars, 50 μM. (C) Albumin flow cytometry analysis cells
at day 14. FAP1 derived cells are shown as one typical example. (D) PAS staining of HLCs to indicate glycogen
synthesis. FAP4 derived cells are shown as one typical example. (E) TTRmRNA expression in HLCs. Mean±SE of
FAP1 to FAP5 are shown. Primary human hepatocytes (PHH) are shown as control. Mean expression was
normalized to housekeeping gene. (F) qRT-PCR analysis of FAP HLCs (grey) and respective iPSCs (white). Mean
±SE of FAP1 to FAP5 are shown. Dotted line indicates same expression relative to human hepatoma HepG2
reference cells line. (G) Mass spectral analysis of cell culture supernatants of HLCs derived from patients FAP1,
FAP3 and FAP5 are shown. Arrows indicate peaks for TTR wild type and variant form.
doi:10.1371/journal.pone.0161455.g003
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analysis. Various liver-specific genes encoding proteins of human hepatocytes, including albu-
min, transferrin and fibronectin, and housekeeping genes (glyceraldehyde 3-phosphate dehy-
drogenase, keratin 8 and copper transport 1) were assessed. None of the genes showed a
significant up- or downregulation in the FAP HLCs after the addition of both compounds indi-
cating a high specificity and a low off-target effect (Fig 4E).
Fig 4. TTR knockdown in FAP patient derived hepatocyte-like cells. (A) qRT-PCR analysis of TTRmRNA expression in
FAP HLCs treated with compounds (n = 5). Mean±SE of FAP1 to FAP5 are shown. (B) Immunocytochemistry stainings of TTR
in FAP HLCs 24 hours after treatment with compounds. FAP4 derived cells are shown as one typical example. Exposure time
was consistently adjusted to 1/6 second. Scale bars, 50 μM. (C) TTRWestern blot analysis of cell culture supernatants derived
from HLCs. FAP4 derived cells are shown as one typical example. (D) Quantification of TTR expression as obtained by
Western blots. Mean±SE of FAP1, FAP4 and FAP5 are shown. (E) qPCR analysis of different hepatic and housekeeping
marker genes in FAP HLCs after treatment with siTTR1 (triangle) and TTR-ASO (squares). Mean of FAP1 to FAP5 are shown.
Data were normalized and set relative to untreated control cells. Absolute ΔΔCt-values are given. Dotted line indicates
significance level. ** p< 0.01; ns, not significant.
doi:10.1371/journal.pone.0161455.g004
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Discussion
Due to invasive procedures, primary cells, e.g. hepatocytes, are rarely available for many appli-
cations without ethical concerns, including the evaluation of novel compounds that have a
high potential to enter clinical application. In this study, the molecular evaluation of novel
compounds for the therapy of FAP patients was assessed in a stem cell-based model. In recent
reports, UCs have been isolated from healthy individuals and patients with a high efficiency of
up to 82% [38,42,43,47]. The efficacy of somatic cell isolation from the urine observed in our
cohort of 21 FAP patients seemed to be moderately lower indicating that disease-specific deter-
minants may modulate the isolation process. However, as cell isolation could be easily repeated
from consecutive donations, a high overall efficacy can be achieved from urine [38]. In addi-
tion, contamination of only two UC cultures has been observed in the study. Contamination
could be further reduced when the cell culture media was supplemented with antibiotics (data
not shown) suggesting that bacterial contamination does not significantly impede efficacy of
the procedure. The marker gene expression profile of the cultivated UCs seems to be diverse,
since uroepithelial progenitor, pericyte, renal and mesenchymal markers are upregulated in the
UCs [33,42,48]. Our characterization of the UCs derived from FAP patients showed high epi-
thelial, fibroblast and renal marker gene expression. Differences of gene expression profiles
may depend on the protocols that were used for UC isolation and propagation or based on the
individual patient cohort. While different cell types derived from urine have been observed ear-
lier [38,42], the likely heterogenous origin of the UC population, e.g. epithelial cells of urinary
bladder, squamous epithelial cells and ureter epithelial cells amongst others,as well as the con-
sequences for reprogramming remains to be further explored.
We routinely observed first iPSC-like colony formation around day 10 after reprogramming
of the FAP patient derived UCs using plasmids that encode EBV elements as also reported by
others [49,50]. The similarity of iPSCs and UCs with regard to their epithelial state might
therefore accelerate reprogramming as compared to fibroblasts that typically form iPSC-like
colonies around week 3 to week 4 [49]. It has been argued that epithelial cells, e.g. keratino-
cytes, do not have to undergo mesenchymal-to-epithelial transition (MET), a possible interme-
diate of the reprogramming events [51–54]. Of note, after reprogramming of the FAP UCs, a
relative high expression of mesodermal markers was observed when iPSCs were regrown in
suspension culture to form EBs. Whether this represents an epigenetic conservation of the UCs
or is due to the reprogramming factors has to be further investigated.
The protocol of hepatic differentiation used in our study resulted in HLCs that share many
characteristics of hepatocytes. However, the characterization of HLCs in our and other studies
also revealed the expression of premature hepatocyte marker, e.g. AFP, suggesting that HLCs
generated from iPSCs represent immature fetal hepatocytes [31,32,35,39,55]. With regard to
TTR expression, our results suggest that at day 3 of HLC differentiation, where endodermal
markers were highly expressed, TTR was not induced. However, it cannot be excluded that
TTR expression of HLCs at d14 may partly originate from premature cells.
One intriguing finding of our study was the high level of TTRmRNA expression which was
found in the HLCs after hepatic differentiation. The levels almost resembled those of human
hepatocytes suggesting that UC derived HLCs represent an ideal cellular model to study the
molecular determinants of FAP. In line, both forms of TTR, the wild type and the variant pro-
tein, were secreted to almost the same amounts into the cell culture medium, a result that dif-
fers from previous findings reported for HLCs that were derived from fibroblasts [32].
The FAP cell culture model established in this study used iPS cell lines from five patients
encoding three major TTR variants. Our data demonstrate that siTTR1 and TTR-ASO, were
equally effective in reducing TTR expression in the five patient cell lines. While minor
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differences could be observed between the five FAP cell lines, levels of TTR knockdown were
significantly reduced in all five patient-derived HLCs. Part of the observed variability could be
due to subtle differences of the cell number at the day of treatment. Off-target effects were not
observed when analyzing a set of 21 hepatocyte-specific genes. Both compounds target regions
located in the highly conserved 3’ UTR of the human TTRmRNA, thus interfere with both the
wild type and more than 130 TTR variants. Although TTR variant-specific inhibition by oligo-
nucleotides has been achieved in vitro [13,14,56], a downregulation of both TTR forms seems
to be favorable from the clinical point of view, since reduction of the overall disease burden in
FAP patients seems to involve wild type TTR [8,15,16].
ALN-TTR02 and IONIS-TTRRx are currently being studied in advanced clinical trials. A
highly efficient, long-term downregulation of serum TTR of about> 80% was reported. Con-
cerning the underlying mechanism, both compounds are remarkably different, since
ALN-TTR02 is a lipid nanoparticle-formulated siRNA that mediates RNA interference via
binding to mRNA/RISC complexes in the cytoplasm, whereas IONIS-TTRRx represents a
naked ASO that is predominantly targeting pre-mRNA in the nucleus via RNaseH [28]. The
FAP patients receive both compounds via different application routes. ALN-TTR02 is given by
intravenous infusion and IONIS-TTRRx by subcutaneously injection. Interestingly, at the level
of the hepatocyte, the molecular events following administration of the oligonucleotides seem
to result in similar efficacy for the TTR knockdown. Of note, although we used similar concen-
trations of the compounds, our iPSC-based cellular model is limited to address the exact stoi-
chiometry needed for the knockdown, since the naked ASO was delivered by a transfection
reagent, whereas the lipid nanoparticle-formulated siRNA could per se mediate cell entry.
To our knowledge this is the first report of an iPSC-based cell model that evaluated com-
pounds currently under clinical investigation. The report suggests that iPSC-based models
could be a valuable tool for the validation of novel compounds before they enter the phase of
clinical studies.
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